CIK 0001750284 · Non-accelerated filer<br>Smaller reporting company
Olema Oncology, Inc.
Sign in to watch- Ticker
- OLMA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 300409740
- Phone
- (415) 651-3316
- Business address
- 365 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- Olema Pharmaceuticals, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-14 | BVF PARTNERS L P/IL Director | Grant or award · Stock Option (Right to buy) | +23,000 | 23,000 | ||
| 2024-06-04 | Graham G. Walmsley Director | Sale | −700,000 | $14.85 | $10.4M | 700,761 |
| 2024-06-04 | Graham G. Walmsley Director | Sale | −475,000 | $14.85 | $7.1M | 708,114 |
| 2024-06-04 | Graham G. Walmsley Director | Sale | −700,000 | $14.85 | $10.4M | 700,761 |
| 2024-06-04 | Graham G. Walmsley Director | Sale | −475,000 | $14.85 | $7.1M | 708,114 |
| 2024-06-04 | Harmon Cyrus Director | Sale 10b5-1 | −5,000 | $12.33 | $62K | 781,283 |
| 2024-06-03 | Harmon Cyrus Director | Sale 10b5-1 | −5,000 | $10.93 | $55K | 786,283 |
| 2024-05-31 | Harmon Cyrus Director | Sale 10b5-1 | −15,000 | $9.41 | $141K | 791,283 |
| 2024-05-24 | Zojwalla Naseem CHIEF MEDICAL OFFICER | Option exercise | +9,460 | $4.87 | $46K | 89,824 |
| 2024-05-24 | Zojwalla Naseem CHIEF MEDICAL OFFICER | Option exercise · Stock Option (Right to Buy) | −9,460 | 126,840 | ||
| 2024-05-06 | Harmon Cyrus Director | Sale 10b5-1 | −5,000 | $10.92 | $55K | 806,283 |
| 2024-04-30 | Harmon Cyrus Director | Sale 10b5-1 | −15,000 | $9.51 | $143K | 811,283 |
| 2024-03-28 | Harmon Cyrus Director | Sale 10b5-1 | −20,000 | $10.97 | $219K | 826,283 |
| 2024-03-18 | Zojwalla Naseem CHIEF MEDICAL OFFICER | Option exercise | +13,700 | $4.87 | $67K | 80,364 |
| 2024-03-18 | Zojwalla Naseem CHIEF MEDICAL OFFICER | Option exercise · Stock Option (Right to Buy) | −13,700 | 136,300 | ||
| 2024-03-05 | RAPPAPORT ANDREW Director | Other disposition | −481,014 | 0 | ||
| 2024-03-05 | RAPPAPORT ANDREW Director | Other acquisition | +385,965 | 385,965 | ||
| 2024-02-29 | Harmon Cyrus Director | Sale 10b5-1 | −24,900 | $12.41 | $309K | 846,383 |
| 2024-02-29 | Harmon Cyrus Director | Sale 10b5-1 | −100 | $13.00 | $1K | 846,283 |
| 2024-02-01 | Myles David C. CH. DISCOV. & NON-CLIN DEV OFF | Grant or award · Stock Option (Right to Buy) | +195,000 | 195,000 |
Page 9 of 11 · 207 trades